Altasciences said its formulation, manufacturing and analytical services facilities in Philadelphia, PA, are undergoing further expansion. The CRO/CDMO is building client-dedicated facilities for Alladapt Immunotherapeutics, a clinical-stage biopharma company developing prescription therapeutics to address IgE-mediated food allergy, with a scheduled completion time in 2023. Having developed the formulation and manufacturing processes to meet all of Alladapt’s Phase I and II clinical trial nee...